Matrix metalloproteinases 2, 3, 13 and their type 2 tissue inhibitor in tumors and plasma of patients with colorectal cancer

被引：9
作者：
Gershtein, E. S. [1 ]
Korotkova, E. A. [1 ]
Prorokov, V. V. [1 ]
Kushlinsky, N. E. [1 ]
机构：
[1] Russian Acad Med Sci, NN Blokhin Canc Res Ctr, Moscow 109801, Russia
来源：
BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE | 2008年 / 145卷 / 03期
基金：
俄罗斯基础研究基金会;
关键词：
matrix metalloproteinase 2; matrix metalloproteinase 3; matrix metalloproteinase 13; type 2 matrix metalloproteinase tissue inhibitor; colorectal cancer;
D O I：
10.1007/s10517-008-0092-8
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Enzyme immunoassay studies revealed increased content of matrix metalloproteinases 2, 3 and 13 in tumors compared to the adjacent histologically unchanged mucosa in 70-90% patients with colorectal cancer, while the increase in the content of type 2 metalloproteinase tissue inhibitor did not reach the level of statistic significance. Plasma concentrations of these proteins did not correlate with the corresponding values in the tumors and did not surpass the normal levels, while their decrease after removal of the primary tumor was observed only in patients with initially high levels of this parameter.
引用
收藏
页码：362 / 366
页数：5
相关论文
共 15 条
  • [1] Belizon Avraham, 2005, Surg Innov, V12, P333, DOI 10.1177/155335060501200408
  • [2] Prognostic significance of expression of matrix metalloproteinase in colorectal adenocarcinomas and their metastases
    Delektorskaya, V. V.
    Perevoshchikov, A. G.
    Golovkov, D. A.
    Kushlinskii, N. E.
    [J]. BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE, 2007, 143 (04) : 455 - 458
  • [3] GERSHTEIN ES, 2007, B EKSP BIOL MED, V143, P438
  • [4] Impact of elective resection on plasma TIMP-1 levels in patients with colon cancer
    Hammer, JH
    Basse, L
    Svendsen, MN
    Werther, K
    Brünnert, N
    Christensen, IJ
    Nielson, HJ
    [J]. COLORECTAL DISEASE, 2006, 8 (03) : 168 - 172
  • [5] Matrix metalloproteinase-9,-3 and tissue inhibitor of matrix metalloproteinase-1 in colorectal cancer:: relationship to clinicopathological variables
    Islekel, Huray
    Oktay, Gulgun
    Terzi, Cem
    Canda, Aras Emre
    Fuzun, Mehmet
    Kupelioglu, Ali
    [J]. CELL BIOCHEMISTRY AND FUNCTION, 2007, 25 (04) : 433 - 441
  • [6] Altered plasma matrix metalloproteinase-9/tissue metalloproteinase-1 concentration during the early postoperative period in patients with colorectal cancer
    Kirman, I
    Jain, S
    Cekic, V
    Belizon, A
    Balik, E
    Sylla, P
    Arnell, T
    Forde, K
    Whelan, RL
    [J]. SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES, 2006, 20 (03): : 482 - 486
  • [7] Antiprotease therapy in cancer: hot or not?
    Lah, TT
    Alonso, MBD
    Van Noorden, CJF
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2006, 6 (03) : 257 - 279
  • [8] Tumor epithelial cell matrix metalloproteinase 9 is a target for antimetastatic therapy in colorectal cancer
    Lubbe, WJ
    Zhou, ZYY
    Fu, WL
    Zuzga, D
    Schulz, S
    Fridman, R
    Muschel, RJ
    Waldman, SA
    Pitari, GM
    [J]. CLINICAL CANCER RESEARCH, 2006, 12 (06) : 1876 - 1882
  • [9] Matrix metalloproteinase inhibitors
    Ramnath N.
    Creaven P.J.
    [J]. Current Oncology Reports, 2004, 6 (2) : 96 - 102
  • [10] Simultaneous determination of matrix metalloproteinase (MMP)-7, MMP-1,-3, and-13 gene expression by multiplex PCR in colorectal carcinomas
    Roeb, E
    Arndt, M
    Jansen, B
    Schumpelick, V
    Matern, S
    [J]. INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2004, 19 (06) : 518 - 524
12